Reckitt Benckiser Group plc
LSE-RKT
Company Overview
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands. It also provides analgesics; sore throat medications; and hair removal products under the Nurofen, Strepsils, and Veet brands. In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; fabric washing; and other hygiene products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as analgesics, adult nutrition products, iron-fortified hypoallergenic baby formula, products for joint issues, and infant and toddler nutrition products, as well as vitamins, minerals, and supplements under the Biofreeze, Airborne, Mead Johnson, Move Free, Enfamil, and Nutramigen brands. Further, it provides probiotics, sore throat pain relief products, Omega products, brain health support products, cleaning and carpet cleaning products, septic tank system treatment products, cough syrups, plant-based laundry products, probiotics, and lubricants under the Digestive Advantage, Cepacol, MegaRed, Neuriva, Easy-Off, RID-X, Delsym, Botanical Origin, Bodi-Ome, and K-Y brands. The company was founded in 1819 and is headquartered in Slough, the United Kingdom.
Name
Reckitt Benckiser Group plc
CEO
Mr. Kristoffer Loe Licht
Website
www.reckitt.com
Sector
Household Products
Year Founded
1819
Profile
Market Cap
£31.76B
EV
£39.9B
Shares Out
693.96M
Revenue
£14.33B
Employees
40,000
Margins
Gross
60.56%
EBITDA
24.71%
Operating
22.63%
Pre-Tax
15.92%
Net
10.78%
FCF
16.42%
Returns (5Yr Avg)
ROA
2.87%
ROTA
-10.68%
ROE
9.4%
ROCE
13.89%
ROIC
8.5%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
£54.99
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
£986M
Net Debt
£8,118M
Debt/Equity
1.13
EBIT/Interest
9.79
Growth (CAGR)
Rev 3Yr
1.55%
Rev 5Yr
2.44%
Rev 10Yr
5.24%
Dil EPS 3Yr
-1.53%
Dil EPS 5Yr
1.68%
Dil EPS 10Yr
-1.8%
Rev Fwd 2Yr
0.55%
EBITDA Fwd 2Yr
1.15%
EPS Fwd 2Yr
2.3%
EPS LT Growth Est
21.04%
Dividends
Yield
—
Payout
90.59%
DPS
£1.96
DPS Growth 3Yr
3.98%
DPS Growth 5Yr
2.54%
DPS Growth 10Yr
3.66%
DPS Growth Fwd 2Yr
5.08%